| Filed On | Filing |
|---|---|
| 04 Nov 2026 | SCHEDULE 13G/A |
| 03 Nov 2026 | 10-Q |
| 02 Nov 2026 |
8-K: Results of Operations and Financial Condition
Third Quarter 2026 Total Revenues Increased 32% Y/Y to $1.025 billion; Growth Driven by 44% Increase in Metabolic Conditions Y/Y, and 12% Increase in Skeletal Conditions Y/Y |
| 06 Oct 2026 |
8-K: Results of Operations and Financial Condition
In connection with its acquisition of Alesta Therapeutics B.V. (Alesta), a Dutch private limited liability company (besloten vennootschap met beperkte aansprakelijkheid), which was completed on August 31, 2026, BioMarin Pharmaceutical In... |
| 01 Oct 2026 |
Form 4: Friberg Gregory R, EVP, Chief R&D Officer
Gave up 4,086 shares to cover exercise price or tax ($245K) |
| 30 Sep 2026 |
8-K: Entry into a Material Definitive Agreement
On September 24, 2026, BioMarin Pharmaceutical Inc. (BioMarin) entered into a Settlement and License Agreement (the Agreement) with Ascendis Pharma A/S (Ascendis). |
| 15 Sep 2026 |
8-K: Other Events
On September 15, 2026, BioMarin Pharmaceutical Inc. (BioMarin) announced its decision to discontinue development of VOXZOGO for children with Noonan syndrome. BioMarin made this decision after assessing a number of factors, including the... |
| 14 Sep 2026 |
Form 4: Plenge Robert M, Director
Received 6,140 shares as a grant or award |
| 14 Sep 2026 |
Form 3: Plenge Robert M, Director
No securities owned |
| 14 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On September 10, 2026, the Board of Directors (the Board) of BioMarin Pharmaceutical Inc. (the Company) increased the size of the Board from ten to eleven members and appointed Robert Plenge, M.D., Ph.D., to the Board, to be effective Se... |
| 03 Sep 2026 |
Form 4: Davis George Eric, EVP, Chief Legal Officer
Sold 17,557 shares ($1.16M) |
| 02 Sep 2026 | 144 |
| 01 Sep 2026 |
8-K: Other Events
As previously reported in the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (“SEC”) on August 18, 2026, BioMarin Pharmaceutical Inc., a Delaware corporation (“BioMarin”), entered into a Share Purchase ... |
| 31 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea |
| 18 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
***Certain identified information has been excluded from the exhibit because it both (i) is not material and (ii) is the type that the company treats as private or confidential. Such omitted information is indicated by brackets (“[***]”)... |
| 06 Aug 2026 | S-8 |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million |
| 13 Jul 2026 |
8-K/A: Other Events
To the Stockholders and the Board of Directors of Amicus Therapeutics, Inc. |
| 04 Jun 2026 |
Form 4: Countouriotis Athena, Director
Received 7,490 shares as a grant or award |
Loading...